In recent years, the life sciences and pharma industries have experienced an increase in regulatory oversight while also facing pressure to respond to global healthcare crises. This tension between regulation and innovation will only increase as security and data privacy concerns limit the ability of many industries to take advantage of public cloud services.
Looking forward, as technology expands, these industries will continue to see a steady escalation in regulations. “By optimizing data sharing and advancing collaboration and innovation, cloud computing can facilitate world-changing discoveries.” Herein lies a unique difficulty for those operating within life sciences and pharma industries — organizations must innovate at the fastest pace possible to compete while still adhering to critical regulatory requirements. As the reliance on technology increases, the pace of R&D in pharma and life sciences is becoming bottlenecked by internal IT processes that are historically unable to compete with the speed of service delivery provided by public clouds.
Recommended AI News: New Slack Innovations and Salesforce Customer 360 Integrations Unlock Team Productivity, Adding Value to the Digital HQ
“In highly regulated sectors, there has been a lot of frustration on the part of teams that feel handcuffed by legacy approaches to IT,” Brad Parks, Chief Product and Marketing Officer at Morpheus Data. “Researchers and scientists need on-demand access to application services, but compliance concerns mean they are not able to simply go to the public cloud like those in other industries.”
This is where Morpheus Data provides innovative hybrid cloud management technology that makes it possible for researchers and teams to move faster while still meeting strict regulatory guidelines and process controls. Through a unified orchestration and automation platform, teams get instant on-demand access to the applications they need to advance their research agenda without having to wait on manual IT processes. Individual users can request organizationally approved application services from a simple self-service portal or API, which means they can constantly analyze data sets, iterate, and test again without delay. At the same time, IT and security teams are able to set strict policies around where applications are deployed and how data is accessed. By retaining critical control of organization-wide governance, IT can protect the organization from risk.
Recommended AI News: Wiha Tools USA Adopts New Salsify Connector to Amazon A+ API
With the Morpheus hybrid cloud management platform, organizations can get the speed and efficiency of the public cloud within the safety and security of their on-premises datacenter. The platform integrates with the datacenter tools and hypervisors that organizations already have, reducing the number of manual tasks that must be performed each time an application service is provisioned. This helps those operating in highly regulated environments access the data sets and applications they need to perform testing in minutes rather than waiting days, weeks, or months for IT to provide assistance.
One Morpheus Data client, AstraZeneca, cites that a service delivery process that previously took 80 hours per server end-to-end can now be accomplished in 27 minutes, start to finish. AstraZeneca also found they saved over six-m************** in IT overhead by automating their hybrid-cloud estate with Morpheus.
In the future, pharma and life sciences organizations that are highly automated will be poised to be able to innovate the fastest. These teams will be able to process patents, receive approvals, and move through the FDA at speed. Automating and orchestrating private cloud environments will allow these teams to operate efficiently while still adhering to strict security and regulation requirements.
Recommended AI News: Delinea Reduces Ransomware Risk for Customers Using Azure AD Government, Makes Secure Remote Access More Seamless
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.